老年弥漫性大B细胞淋巴瘤患者R-CHOP后接受90Y-epratuzumab tetraxetan分次抗CD22放射免疫巩固治疗:一项前瞻性单组2期试验
这项在法国28家医院开展的前瞻性单组2期试验纳入60-80岁、不适合移植的初治弥漫性大B细胞淋巴瘤患者,R-CHOP诱导后对缓解者给予两剂90Y-epratuzumab tetraxetan放射免疫巩固。中位随访37个月时估计2年无事件生存率为75%(95%CI 63-84),3-4级血小板减少和中性粒细胞减少常见。作者认为该巩固方案可能适用,但需进一步对照研究。
要点
- R-CHOP后90Y-epratuzumab tetraxetan巩固的估计2年无事件生存率为75%(95%CI 63-84)。
- 57例接受放射免疫治疗者中,3-4级血小板减少48例(84%)、中性粒细胞减少45例(79%)。
- 1例在放射免疫治疗后28个月发生骨髓增生异常综合征,1例在5个月后发生急性髓系白血病。
核心结论
- 作者认为,对老年晚期弥漫性大B细胞淋巴瘤患者,诱导化疗后以90Y-epratuzumab tetraxetan分次放射免疫治疗进行缓解巩固可能适用,但需要进一步的对照研究。
研究设计与样本
- 前瞻性、单组、2期试验,在法国28家医院开展,患者从17家医院招募。
- 纳入60-80岁、初治、不适合移植的弥漫性大B细胞淋巴瘤患者,为 bulky 2-3期或3-4期CD20阳性。
- 患者接受6周期R-CHOP(每14天一次:利妥昔单抗375 mg/m2、环磷酰胺750 mg/m2、多柔比星50 mg/m2、长春新碱1.4 mg/m2(上限2 mg)均第1天给药,泼尼松40 mg/m2每日连用5天)。
- R-CHOP后6-8周,缓解者接受两剂15 mCi/m2(555 MBq/m2)90Y-epratuzumab tetraxetan,间隔1周给药。
- 主要终点为所有注册合格且接受至少1天研究治疗患者的2年无事件生存率;安全性分析在同一人群中进行。
主要发现
- 中位随访37个月(IQR 30-44),估计2年无事件生存率为75%(95%CI 63-84)。
- 放射免疫治疗毒性包括3-4级血小板减少48/57例(84%)和中性粒细胞减少45/57例(79%)。
- 1例患者在放射免疫治疗后28个月发生骨髓增生异常综合征,1例患者在放射免疫治疗后5个月发生急性髓系白血病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者在解释中指出需要进一步的对照研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radioimmunotherapy represents a potential option as consolidation after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for transplantation. We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 90Y-epratuzumab tetraxetan as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with diffuse large B-cell lymphoma. METHODS: We did a prospective, single-group, phase 2 trial at 28 hospitals in France, with patients recruited from 17 hospitals. Eligible patients were aged 60-80 years with bulky stage 2-3 or stage 3-4 CD20-positive diffuse large B-cell lymphoma, previously untreated, and not eligible for transplantation. Patients received six cycles of R-CHOP (rituximab [375 mg/m2], cyclophosphamide [750 mg/m2], doxorubicin [50 mg/m2], and vincristine [1·4 mg/m2, up to 2 mg] all on day 1, and prednisone [40 mg/m2] daily for 5 days), administered every 14 days. 6-8 weeks after R-CHOP, responders received two doses of 15 mCi/m2 (555 MBq/m2) 90Y-epratuzumab tetraxetan administered 1 week apart. The primary endpoint was 2 year event-free survival in all registered eligible patients who received at least 1 day of study treatment; the safety analysis was done in the same population. This trial is registered with ClinicalTrials.gov, number NCT00906841. FINDINGS: Between Oct 22, 2008, and Dec 16, 2010, we recruited 75 patients, of whom four (5%) were excluded after central pathology review; hence, 71 (95%) patients were included in the analysis. All patients started induction treatment; 57 (80%) received radioimmunotherapy. With a median follow-up of 37 months (IQR 30-44), the estimated 2 year event-free survival was 75% (95% CI 63-84). Radioimmunotherapy toxicity consisted of grade 3-4 thrombocytopenia in 48 (84%) of 57 patients and neutropenia in 45 (79%) of 57 patients. One patient developed myelodysplastic syndrome 28 months after receiving radioimmunotherapy and one patient developed acute myeloid leukaemia 5 months after receiving radioimmunotherapy. INTERPRETATION: Fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan might be appropriate for response consolidation after induction chemotherapy in older patients with advanced diffuse large B-cell lymphoma, but further comparative studies are needed. FUNDING: Immunomedics, Amgen, Canceropôle Grand Ouest, the GOELAMS/LYSA group and the French National Agency for Research (Investissements d'Avenir).
引用
- Kraeber-Bodere F, Pallardy A, Maisonneuve H, et al. Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematol. 2016. PMID: 27964867. doi:10.1016/S2352-3026(16)30168-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。